Bromodel Tablet
Bromocriptine
2.5mg
Opsonin Pharma Limited
| Pack size | 30's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 12.00 AED |
Indications
Bromodel Tablet is used for:
Parkinson's disease, Galactorrhoea, Hypogonadism, Infertility, Acromegaly, Lactation suppression, Benign breast and Menstrual disorders, Amenorrhea, Hyperprolactinaemia
Adult Dose
Adult:
Parkinson's disease
As an adjunct to levodopa:
1st wk: 1-1.25 mg at night,
2nd wk: 2-2.5 mg at night;
3rd wk: 2.5 mg twice daily;
4th wk: 2.5 mg 3 times/day, then increase as needed.
Maintenance: 10-40 mg/day.
Hyperprolactinemia
Initial: 1.25-2.5 mg PO once daily
May increase by 2.5 mg/day in 2-7 Days
Usual therapeutic dosage 5-7.5 mg/day, ranges from 2.5-15 mg/day
Up to 30 mg/day has been used in some patients with amenorrhea &/or galactorrhea
Acromegaly
1.25-2.5 mg PO qHS for 3 days
May increase by 1.25-2.5 mg/day at in 3-7 Days
Not to exceed 100 mg/day
Adjunct to surgery and radiotherapy in patients w/ acromegaly Initial:
2.5 mg twice daily, increase slowly, up to 5 mg 6 hourly if needed.
Lactation suppression
2.5 mg/day for 2-3 days, up to 2.5 mg twice daily for 14 days.
Prevention of puerperal lactation
2.5 mg on the day of delivery, then 2.5 mg twice daily for 14 days.
Cyclical benign breast and menstrual disorders
2.5 mg twice daily.
Child Dose
Hyperprolactinemia
11-15 years: 1.25-2.5 mg PO once daily (initially)
Maintenance: 2.5-10 mg/day
Renal Dose
Renal impairment: Safety and efficacy has not been established
Administration
Should be taken with food.
Contra Indications
Breast carcinoma, hypersensitivity to ergot alkaloids,
Hypersensitivity to bromocriptine, ergot-related drugs, or to any of the excipients
Uncontrolled hypertension
Pregnancy in patients treated for hyperprolactinemia
Postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions
Precautions
Increased risk of conception, patients with peptic ulcer, diabetes, diabetic retinopathy, impaired hepatic or renal function, pleuropulmonary signs and symptoms, history of psychosis, CV disease, dementia or concurrent antihypertensive therapy, ability to drive vehicles or operating machinery may be impaired.
MONITORING PARAMETERS
Specialist evaluation—monitor for pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss in macroprolactinoma.
Monitor for fibrotic disease.
Monitor blood pressure for a few days after starting treatment and following the dosage increase.
Pregnancy-Lactation
Pregnancy
Safety of Bromocriptine treatment during pregnancy to the mother and fetus has not been established
If pregnancy occurs during Bromocriptine administration, careful observation of these patients is mandatory
Prolactin-secreting adenomas may expand and compression of optic/other cranial nerves may occur, emergency pituitary surgery becoming necessary; in most cases, the compression resolves following delivery
Reinitiation of Bromocriptine treatment has been reported to produce improvement in the visual fields of patients in whom nerve compression has occurred during pregnancy
In patients being treated for hyperprolactinemia, Bromocriptine should be withdrawn when pregnancy is diagnosed
Acromegaly, prolactinoma, or Parkinson's disease
Patients who subsequently become pregnant, determine whether continuing therapy is medically necessary or can discontinue
If it is continued, discontinue therapy in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless the withdrawal of Bromocriptine is considered to be medically contraindicated
Lactation
Avoid use during lactation in postpartum women
Interactions
Bioavailability increased if given along with erythromycin. Alcohol reduces tolerance to bromocriptine and vice-versa. Effects of antihypertensives may be potentiated. Avoid concurrent psychotropic.
Contraindicated (16)
almotriptan
chloramphenicol
eletriptan
frovatriptan
glyceryl trinitrate pr
lopinavir
naratriptan
nitroglycerin IV
nitroglycerin sublingual
nitroglycerin topical
nitroglycerin transdermal
nitroglycerin translingual
posaconazole
sumatriptan
sumatriptan intranasal
zolmitriptan
Adverse Effects
Side effects of Bromocriptine :
>10%
Nausea (49%),Hypotension (30%),Headache (19%),Dizziness (17%)
1-10%
Abdominal cramps,Anorexia,Constipation,Dyspepsia,Dysphagia,Epigastric pain,GI hemorrhage,Vomiting,Drowsiness,Fatigue,Faintness,Hallucinations Visual,Insomnia,Lightheadedness,Nighmares,Paranoia,Psychosis,Seizure,Vertigo,Arrhythmias,Bradycardia,Hypertension,MI,Mottled skin,Orthostasis,Vasospasm,Palpitations,Pericardial effusions,Raynaud's syndrome exacertabtion,Syncope,Blepharospasm,BUN increased,Burning discomfort of the eye,Diplopia,Facial pallor,Leg cramps,Nasal congestion,Rash,Urticaria
Mechanism of Action
Bromocriptine is a dopamine D2 and D3-agonist which works by activating postsynaptic dopamine receptors in the tuberoinfundibular and nigrostriatal pathways. It also inhibits the secretion of prolactin from the anterior pituitary and is used in the treatment of prolactinoma and in endocrinological disorders.
Note
Bromodel 2.5mg Tablet manufactured by Opsonin Pharma Limited. Its generic name is Bromocriptine. Bromodel is availble in Bangladesh.
Farmaco BD drug index information on Bromodel Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.